{"success":true,"data":{"pressRelease":{"id":"168971","rtpr_id":"nGNX4Zc8Nl-20261014","ticker":"BLO","exchange":"","all_tickers":["BLO"],"title":"Cannabix Technologies Files Provisional Patent Application for BCU-Enabled Point-of-Care Marijuana Breath Testing","author":"Globe Newswire","published_at":"2026-10-14T12:45:00.052Z","article_body":"VANCOUVER, British Columbia, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Cannabix\nTechnologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the\n“Company” or “Cannabix”), a developer of marijuana and alcohol breath\ntesting technologies, announces that it has filed a provisional patent\napplication in the United States covering a novel rapid point-of-care (\"POCT\")\nmarijuana breath test method designed to detect delta-9 tetrahydrocannabinol\n(\"THC\"), the primary psychoactive component of cannabis, from breath samples.\n\nThe provisional patent application covers new testing methods under\ndevelopment that combine the Company's proprietary Breath Collection Unit\n(BCU) and Breath Cartridge (BC) technologies with lateral flow (LF) rapid test\nplatforms and custom-designed components optimized for point-of-care use. The\nportable BCU is designed to control, collect and concentrate standardized\nbreath samples and efficiently transfer breath analytes into a workflow\ncompatible with screening and analysis technologies.  Safety advocates,\nemployers, and industry stakeholders are increasingly seeking cost-effective,\nrapid point-of-care marijuana screening solutions that can be deployed using\nestablished drug-testing workflows, while offering the unique advantage of\nassessing recent cannabis use through breath samples.\n\nIn recent months, Company scientists have advanced research and development\nefforts to pair its BCU and Breath Cartridge with next-generation lateral flow\nassay platforms and custom-designed POCT components. The approach combines the\nBCU’s ability to efficiently capture THC-containing breath aerosols using\nair-volume control and pressure-assisted concentration onto its proprietary\nBreath Cartridge, particularly during the period immediately following\ncannabis consumption, addressing a central challenge in rapid THC detection.\nBy presenting the lateral flow assay with a concentrated, standardized sample\nrather than an untreated specimen, the BCU and Breath Cartridge is designed to\nhelp address the sensitivity limitations associated with detecting THC at the\npoint of collection. The combined approach is being developed with the goal of\nenabling a cost effective, rapid point-of-care THC breath screening test (a\n\"Rapid Breath Test Kit\") capable of delivering results within minutes from a\nbreath sample.\n\nThe proposed POCT workflow is designed to provide a rapid on-site screening\nresult from the initial BCU collection. If the screening result is positive\nand evidentiary confirmation is required, the BCU can then be used to collect\na confirmation sample under chain-of-custody procedures using the Company's\nestablished Marijuana Breath Test (MBT) process. The confirmation sample is\nanalyzed using a validated LC-MS laboratory method, which has been published\nin the Journal of Analytical Toxicology and is currently in use with clients.\nImportantly, the establishment of the MBT represents a technological\nfoundation underpinning the Company's efforts to develop a breath-based\npoint-of-care THC screening test. This proposed approach is intended to\ncombine the speed and convenience of on-site screening with access to a\nconfirmatory laboratory result when required.\n\nThe performance of Cannabix’s POCT approach depends on the integrated\noperation of the BCU, Breath Cartridge and pre-concentration methods—not on\nany single commercially available test component. This integrated platform\nprovides the foundation for deploying rapid marijuana breath screening in\npractical, real-world settings. The proposed Rapid Breath Test Kit remains in\nthe early stages of development and will require further technical\nadvancements, including enhanced analytical sensitivity, optimization of\nsample collection and recovery methods, and the development of a fully\nintegrated testing workflow.\n\nThe provisional patent application builds on Cannabix’s proprietary\nbreath-sampling and sample-preparation intellectual property. The development\nof a practical and cost-effective Rapid Breath Test Kit reflects Cannabix's\nongoing commitment to advancing innovative point-of-care breath testing\nsolutions for real-world applications.  \n\nAbout Cannabix Technologies Inc.\n\nCannabix Technologies Inc. is a leading developer of breath-based technologies\ndesigned to enhance public safety and reduce impairment-related risks in\nworkplaces, law enforcement, and a range of different settings. The Marijuana\nBreath Test (MBT) targets delta-9 THC—the primary psychoactive compound in\ncannabis—in breath, providing a practical solution for identifying recent\nmarijuana use.\n\nThe BreathLogix, unmanned alcohol screening solution supports organizations in\nproactively monitoring alcohol impairment, strengthening safety protocols, and\npromoting responsible behavior. By delivering innovative, non-invasive\nscreening tools, Cannabix aims to help reduce accidents, improve\ndecision-making, and protect organizations, individuals and the public at\nlarge. Visit www.cannabixtechnologies.com\n\nWe seek Safe Harbor.\n\nOn behalf of the Board of Directors\n\n“Rav Mlait”\n\nCEO\nCannabix Technologies Inc.\n\nFor further information, contact the Company at info@cannabixtechnologies.com\n\nCautionary Statement Regarding Forward-Looking Statements\n\nThis news release contains certain \"forward-looking statements\" and\n\"forward-looking information\" within the meaning of applicable This news\nrelease contains certain \"forward-looking statements\" and \"forward-looking\ninformation\" within the meaning of applicable Canadian securities laws\n(collectively, \"forward-looking statements\"). All statements contained in this\nnews release that are not statements of historical fact are forward-looking\nstatements, including, without limitation, statements regarding: the\ndevelopment, performance, validation, commercialization, deployment, market\nacceptance, and adoption of the Company's proposed Rapid Breath Test Kit,\nMarijuana Breath Test (\"MBT\"), Breath Collection Unit (\"BCU\"), Breath\nCartridge technologies, and BreathLogix technologies; the potential\neffectiveness of the Company's BCU-enabled point-of-care marijuana breath\ntesting methods; the ability of the Company's technologies to collect,\nconcentrate, recover, detect, analyze, or confirm THC or other analytes from\nbreath samples; anticipated customer demand and market opportunities for rapid\npoint-of-care marijuana screening solutions; the integration of lateral flow\nassay technologies and custom-designed testing components with the Company's\nproprietary breath collection platform; the ability to provide rapid screening\nand laboratory confirmation workflows; intellectual property development,\nprotection, prosecution, and the potential issuance of patents based on\nprovisional or future patent applications; future technological enhancements,\nproduct development efforts, and research initiatives; manufacturing scale-up\nand operational readiness; the Company's ability to establish and expand\nreseller, distribution, laboratory, strategic, research, and commercial\nrelationships; expansion into additional drug-testing, workplace safety,\nregulatory approvals, certifications, and compliance; future financings; and\nthe achievement of anticipated business, commercial, scientific, technical, or\noperational milestones.  Forward-looking statements are often identified by\nwords such as \"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"develop,\"\n\"estimate,\" \"expect,\" \"intend,\" \"may,\" \"opportunity,\" \"plan,\" \"potential,\"\n\"propose,\" \"project,\" \"seek,\" \"target,\" \"will,\" and similar expressions, or\nstatements that certain events or conditions \"may,\" \"could,\" \"should,\" or\n\"will\" occur. These forward-looking statements are based on management's\ncurrent beliefs, expectations, assumptions, and estimates as of the date of\nthis news release.  Forward-looking statements are subject to significant\nknown and unknown risks, uncertainties, assumptions, and other factors, many\nof which are beyond the Company's control, that could cause actual results,\nperformance, achievements, or developments to differ materially from those\nexpressed or implied by such forward-looking statements. Such factors include,\nwithout limitation: risks related to research, product development, testing,\noptimization, validation, and commercialization; the possibility that the\nCompany's proposed Rapid Breath Test Kit or related technologies may not\nachieve anticipated performance, sensitivity, accuracy, reliability, or\ncommercial objectives; uncertainty regarding customer acceptance and market\nadoption of the Company's technologies; risks associated with the integration\nof lateral flow assays, collection devices, analytical methods, and other\ntesting components; uncertainty regarding the timing, scope, or outcome of\npatent applications and intellectual property protection efforts; competition\nfrom existing and future products and technologies; manufacturing, supply\nchain, scaling, and deployment risks; the ability to secure and maintain\nstrategic relationships, laboratory partnerships, reseller arrangements,\nresearch collaborations, and commercial agreements; risks associated with\nintellectual property protection and enforcement; changes in laws,\nregulations, standards, or governmental policies affecting cannabis, alcohol,\nworkplace testing, diagnostic technologies, or related industries; regulatory\napproval, clearance, certification, and compliance risks; technological\nlimitations or challenges; dependence on third-party suppliers, laboratories,\nmanufacturers, developers, and service providers; financing and capital market\nrisks; economic, tariff, industry, and market conditions; and the possibility\nthat anticipated opportunities in drug testing, workplace safety, health,\ndiagnostics, breath analysis, or other adjacent markets may not materialize or\nmay not be commercially successful. Although the Company believes that the\nexpectations reflected in the forward-looking statements are reasonable, there\ncan be no assurance that such expectations will prove to be correct. Readers\nare cautioned not to place undue reliance on forward-looking statements, as\nactual results and future events may differ materially from those anticipated.\nThe forward-looking statements contained in this news release are made as of\nthe date hereof, and the Company undertakes no obligation to update or revise\nany forward-looking statements, whether as a result of new information, future\nevents, or otherwise, except as required by applicable securities laws.\n\nThe CSE has not reviewed and does not accept responsibility for the adequacy\nor accuracy of this release.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c82e010e-984e-4788-b222-2539a90d3394)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4Zc8Nl-20261014","title":"Cannabix Technologies Files Provisional Patent Application for BCU-Enabled Point-of-Care Marijuana Breath Testing","author":"Globe Newswire","ticker":"BLO","created":"2026-10-14T12:45:00.052Z","tickers":["BLO"],"exchange":"","article_body":"VANCOUVER, British Columbia, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Cannabix\nTechnologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the\n“Company” or “Cannabix”), a developer of marijuana and alcohol breath\ntesting technologies, announces that it has filed a provisional patent\napplication in the United States covering a novel rapid point-of-care (\"POCT\")\nmarijuana breath test method designed to detect delta-9 tetrahydrocannabinol\n(\"THC\"), the primary psychoactive component of cannabis, from breath samples.\n\nThe provisional patent application covers new testing methods under\ndevelopment that combine the Company's proprietary Breath Collection Unit\n(BCU) and Breath Cartridge (BC) technologies with lateral flow (LF) rapid test\nplatforms and custom-designed components optimized for point-of-care use. The\nportable BCU is designed to control, collect and concentrate standardized\nbreath samples and efficiently transfer breath analytes into a workflow\ncompatible with screening and analysis technologies.  Safety advocates,\nemployers, and industry stakeholders are increasingly seeking cost-effective,\nrapid point-of-care marijuana screening solutions that can be deployed using\nestablished drug-testing workflows, while offering the unique advantage of\nassessing recent cannabis use through breath samples.\n\nIn recent months, Company scientists have advanced research and development\nefforts to pair its BCU and Breath Cartridge with next-generation lateral flow\nassay platforms and custom-designed POCT components. The approach combines the\nBCU’s ability to efficiently capture THC-containing breath aerosols using\nair-volume control and pressure-assisted concentration onto its proprietary\nBreath Cartridge, particularly during the period immediately following\ncannabis consumption, addressing a central challenge in rapid THC detection.\nBy presenting the lateral flow assay with a concentrated, standardized sample\nrather than an untreated specimen, the BCU and Breath Cartridge is designed to\nhelp address the sensitivity limitations associated with detecting THC at the\npoint of collection. The combined approach is being developed with the goal of\nenabling a cost effective, rapid point-of-care THC breath screening test (a\n\"Rapid Breath Test Kit\") capable of delivering results within minutes from a\nbreath sample.\n\nThe proposed POCT workflow is designed to provide a rapid on-site screening\nresult from the initial BCU collection. If the screening result is positive\nand evidentiary confirmation is required, the BCU can then be used to collect\na confirmation sample under chain-of-custody procedures using the Company's\nestablished Marijuana Breath Test (MBT) process. The confirmation sample is\nanalyzed using a validated LC-MS laboratory method, which has been published\nin the Journal of Analytical Toxicology and is currently in use with clients.\nImportantly, the establishment of the MBT represents a technological\nfoundation underpinning the Company's efforts to develop a breath-based\npoint-of-care THC screening test. This proposed approach is intended to\ncombine the speed and convenience of on-site screening with access to a\nconfirmatory laboratory result when required.\n\nThe performance of Cannabix’s POCT approach depends on the integrated\noperation of the BCU, Breath Cartridge and pre-concentration methods—not on\nany single commercially available test component. This integrated platform\nprovides the foundation for deploying rapid marijuana breath screening in\npractical, real-world settings. The proposed Rapid Breath Test Kit remains in\nthe early stages of development and will require further technical\nadvancements, including enhanced analytical sensitivity, optimization of\nsample collection and recovery methods, and the development of a fully\nintegrated testing workflow.\n\nThe provisional patent application builds on Cannabix’s proprietary\nbreath-sampling and sample-preparation intellectual property. The development\nof a practical and cost-effective Rapid Breath Test Kit reflects Cannabix's\nongoing commitment to advancing innovative point-of-care breath testing\nsolutions for real-world applications.  \n\nAbout Cannabix Technologies Inc.\n\nCannabix Technologies Inc. is a leading developer of breath-based technologies\ndesigned to enhance public safety and reduce impairment-related risks in\nworkplaces, law enforcement, and a range of different settings. The Marijuana\nBreath Test (MBT) targets delta-9 THC—the primary psychoactive compound in\ncannabis—in breath, providing a practical solution for identifying recent\nmarijuana use.\n\nThe BreathLogix, unmanned alcohol screening solution supports organizations in\nproactively monitoring alcohol impairment, strengthening safety protocols, and\npromoting responsible behavior. By delivering innovative, non-invasive\nscreening tools, Cannabix aims to help reduce accidents, improve\ndecision-making, and protect organizations, individuals and the public at\nlarge. Visit www.cannabixtechnologies.com\n\nWe seek Safe Harbor.\n\nOn behalf of the Board of Directors\n\n“Rav Mlait”\n\nCEO\nCannabix Technologies Inc.\n\nFor further information, contact the Company at info@cannabixtechnologies.com\n\nCautionary Statement Regarding Forward-Looking Statements\n\nThis news release contains certain \"forward-looking statements\" and\n\"forward-looking information\" within the meaning of applicable This news\nrelease contains certain \"forward-looking statements\" and \"forward-looking\ninformation\" within the meaning of applicable Canadian securities laws\n(collectively, \"forward-looking statements\"). All statements contained in this\nnews release that are not statements of historical fact are forward-looking\nstatements, including, without limitation, statements regarding: the\ndevelopment, performance, validation, commercialization, deployment, market\nacceptance, and adoption of the Company's proposed Rapid Breath Test Kit,\nMarijuana Breath Test (\"MBT\"), Breath Collection Unit (\"BCU\"), Breath\nCartridge technologies, and BreathLogix technologies; the potential\neffectiveness of the Company's BCU-enabled point-of-care marijuana breath\ntesting methods; the ability of the Company's technologies to collect,\nconcentrate, recover, detect, analyze, or confirm THC or other analytes from\nbreath samples; anticipated customer demand and market opportunities for rapid\npoint-of-care marijuana screening solutions; the integration of lateral flow\nassay technologies and custom-designed testing components with the Company's\nproprietary breath collection platform; the ability to provide rapid screening\nand laboratory confirmation workflows; intellectual property development,\nprotection, prosecution, and the potential issuance of patents based on\nprovisional or future patent applications; future technological enhancements,\nproduct development efforts, and research initiatives; manufacturing scale-up\nand operational readiness; the Company's ability to establish and expand\nreseller, distribution, laboratory, strategic, research, and commercial\nrelationships; expansion into additional drug-testing, workplace safety,\nregulatory approvals, certifications, and compliance; future financings; and\nthe achievement of anticipated business, commercial, scientific, technical, or\noperational milestones.  Forward-looking statements are often identified by\nwords such as \"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"develop,\"\n\"estimate,\" \"expect,\" \"intend,\" \"may,\" \"opportunity,\" \"plan,\" \"potential,\"\n\"propose,\" \"project,\" \"seek,\" \"target,\" \"will,\" and similar expressions, or\nstatements that certain events or conditions \"may,\" \"could,\" \"should,\" or\n\"will\" occur. These forward-looking statements are based on management's\ncurrent beliefs, expectations, assumptions, and estimates as of the date of\nthis news release.  Forward-looking statements are subject to significant\nknown and unknown risks, uncertainties, assumptions, and other factors, many\nof which are beyond the Company's control, that could cause actual results,\nperformance, achievements, or developments to differ materially from those\nexpressed or implied by such forward-looking statements. Such factors include,\nwithout limitation: risks related to research, product development, testing,\noptimization, validation, and commercialization; the possibility that the\nCompany's proposed Rapid Breath Test Kit or related technologies may not\nachieve anticipated performance, sensitivity, accuracy, reliability, or\ncommercial objectives; uncertainty regarding customer acceptance and market\nadoption of the Company's technologies; risks associated with the integration\nof lateral flow assays, collection devices, analytical methods, and other\ntesting components; uncertainty regarding the timing, scope, or outcome of\npatent applications and intellectual property protection efforts; competition\nfrom existing and future products and technologies; manufacturing, supply\nchain, scaling, and deployment risks; the ability to secure and maintain\nstrategic relationships, laboratory partnerships, reseller arrangements,\nresearch collaborations, and commercial agreements; risks associated with\nintellectual property protection and enforcement; changes in laws,\nregulations, standards, or governmental policies affecting cannabis, alcohol,\nworkplace testing, diagnostic technologies, or related industries; regulatory\napproval, clearance, certification, and compliance risks; technological\nlimitations or challenges; dependence on third-party suppliers, laboratories,\nmanufacturers, developers, and service providers; financing and capital market\nrisks; economic, tariff, industry, and market conditions; and the possibility\nthat anticipated opportunities in drug testing, workplace safety, health,\ndiagnostics, breath analysis, or other adjacent markets may not materialize or\nmay not be commercially successful. Although the Company believes that the\nexpectations reflected in the forward-looking statements are reasonable, there\ncan be no assurance that such expectations will prove to be correct. Readers\nare cautioned not to place undue reliance on forward-looking statements, as\nactual results and future events may differ materially from those anticipated.\nThe forward-looking statements contained in this news release are made as of\nthe date hereof, and the Company undertakes no obligation to update or revise\nany forward-looking statements, whether as a result of new information, future\nevents, or otherwise, except as required by applicable securities laws.\n\nThe CSE has not reviewed and does not accept responsibility for the adequacy\nor accuracy of this release.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c82e010e-984e-4788-b222-2539a90d3394)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-14T12:45:00.138524029Z","server_sent_at_ms":1791981900138},"received_at":"2026-10-14T12:45:00.278Z","source_url":null},"analysis":{"id":"157220","press_release_id":"168971","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["Rapid Breath Test Kit is in early-stage development with no certainty of commercialization","pre-revenue micro-cap reliant on future financings (per forward-looking statement risk factors)"],"eventType":"product_launch","narrative":"Cannabix Technologies filed a U.S. provisional patent application covering a rapid point-of-care marijuana breath test method combining its BCU and Breath Cartridge technologies with lateral flow assay platforms.\n\nThe proposed Rapid Breath Test Kit is designed to detect delta-9 THC from breath within minutes, with a chain-of-custody confirmation workflow via the company's lab-based Marijuana Breath Test process.\n\nThe kit remains in early development and still requires sensitivity improvements and workflow integration before commercialization, so the patent filing is an incremental IP milestone rather than a revenue event.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Early-stage IP filing for a POCT THC breath test -- incremental news, watch for commercialization milestones."},"keyFigures":{"customDimensions":{"development_stage":"early stages of development"}},"namedEntities":{"people":[{"name":"Rav Mlait","role":"CEO"}],"products":["Breath Collection Unit (BCU)","Breath Cartridge","Rapid Breath Test Kit","Marijuana Breath Test (MBT)","BreathLogix"],"companies":[{"name":"Cannabix Technologies Inc.","ticker":"BLO"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"A provisional patent application for a technology still in early-stage development with no revenue, approval, or commercial milestone attached. Incremental IP news only."},"tickerRelevance":{"others":[],"primary":"BLO"},"globalImportance":10,"audienceRelevance":8,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"provisional-patent-filing","issuerAuthored":true,"commercialReadiness":"early-stage"}},"event_type":"product_launch","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":1,"narrative":"Cannabix Technologies filed a U.S. provisional patent application covering a rapid point-of-care marijuana breath test method combining its BCU and Breath Cartridge technologies with lateral flow assay platforms.\n\nThe proposed Rapid Breath Test Kit is designed to detect delta-9 THC from breath within minutes, with a chain-of-custody confirmation workflow via the company's lab-based Marijuana Breath Test process.\n\nThe kit remains in early development and still requires sensitivity improvements and workflow integration before commercialization, so the patent filing is an incremental IP milestone rather than a revenue event.","key_figures":{"customDimensions":{"development_stage":"early stages of development"}},"named_entities":{"people":[{"name":"Rav Mlait","role":"CEO"}],"products":["Breath Collection Unit (BCU)","Breath Cartridge","Rapid Breath Test Kit","Marijuana Breath Test (MBT)","BreathLogix"],"companies":[{"name":"Cannabix Technologies Inc.","ticker":"BLO"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T12:45:05.059Z","global_importance":10,"audience_relevance":8,"importance_components":{"tickerTier":"micro-cap","eventGravity":"provisional-patent-filing","issuerAuthored":true,"commercialReadiness":"early-stage"}},"durationMs":4758,"modelName":"glm-5.3-flashx"}}